Statement on political and business situation

Beximco Pharmaceuticals Ltd

13 August 2024

 

13 August 2024

BEXIMCO PHARMACEUTICALS LIMITED

Statement on current political and business situation in Bangladesh

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, provides a statement following continued reports of civil unrest across Bangladesh and the appointment of an interim government.

The Company can confirm that, to date, there has been no significant damage to its manufacturing and distribution facilities. However, disruption in various parts of the country means that, in the interests of employee safety and welfare, distribution has been reduced - but this is now returning to normal levels. The interim government of Bangladesh has indicated that it intends to address any ongoing unrest as a priority and we expect to be able to resume normal distribution in the coming days. We do not currently expect this disruption to have a material impact on our financial expectations for the year. Further announcements will be made as appropriate.

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

S M Rabbur Reza, Chief Operating Officer

Tel: [phone], Ext.20111

Mohammad Ali Nawaz, Chief Financial Officer

Tel: [phone], Ext.20030

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott / Adam Dawes

Tel: [phone] / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: [phone]

FTI Consulting

Simon Conway / Victoria Foster Mitchell / Sam Purewal

Tel: [phone]

Notes to Editors

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5700 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

 

END